Preferred Label : nilotinib;

MeSH note : antineoplastic agent; structure in first source;

MeSH synonym : 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;

MeSH hyponym : benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate (1:1:2); benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); nilotinib hydrochloride; Tasigna; nilotinib hydrochloride monohydrate; benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate; benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate (2:2:3); benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride, hydrate (1:2:2); AMN-107; AMN 107;

MeSH Related Number : 5JHU0N1R6K; FQV3UFL546; K37N7BYX3X; WM15I3PF3G; Y37S7HA3BC;

Is substance : O;

UNII : F41401512X;

Details


Main resources

You can consult :


https://www.has-sante.fr/portail/jcms/c_2853363/fr/tasigna
2018
false
France
French
English
evaluation of the transparency committee
child
nilotinib
Tyrosine Kinase Inhibitors
leukemia, myeloid, chronic-phase
nilotinib
administration, oral
nilotinib
insurance, health, reimbursement
antineoplastic agents
protein-tyrosine kinases
pyrimidines

---
https://www.has-sante.fr/portail/jcms/c_2883466/fr/tasigna
2018
false
true
false
France
nilotinib
treatment outcome
insurance, health, reimbursement
nilotinib
evaluation of the transparency committee
nilotinib hydrochloride hydrate
nilotinib
pyrimidines
nilotinib
pyrimidines

---
In : Bulletin du Cancer Volume 103, Issue 2, February 2016, Pages 180–189 - Open Access
http://www.sciencedirect.com/science/article/pii/S0007455115003689
2016
false
false
false
Netherlands
French
journal article
nilotinib
nilotinib
protein-tyrosine kinases
leukemia, myeloid, chronic-phase
cardiovascular diseases
risk factors
risk assessment
cardiovascular diseases
practice guideline
Tyrosine Kinase Inhibitors
nilotinib
nilotinib
pyrimidines
pyrimidines

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles

---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines

---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/tasigna-1438.html
2012
false
Canada
English
French
evaluation of the transparency committee
Tyrosine Kinase Inhibitors
fusion proteins, bcr-abl
adult
treatment outcome
Cost-Benefit analysis
clinical trials, phase iii as topic
nilotinib
administration, oral
leukemia, myelogenous, chronic, bcr-abl positive
nilotinib
protein-tyrosine kinases
protein kinase inhibitors
antineoplastic agents
pyrimidines
drug evaluation

---
https://www.ema.europa.eu/medicines/human/EPAR/Tasigna
2012
false
United Kingdom
French
English
syndication feed
Tyrosine Kinase Inhibitors
fusion proteins, bcr-abl
pyrimidines
leukemia, myelogenous, chronic, bcr-abl positive
protein kinase inhibitors
pyrimidines
protein kinase inhibitors
orphan drug production
capsules
administration, oral
adult
drug evaluation
treatment outcome
drug approval
drug labeling
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antineoplastic agents
antineoplastic agents
nilotinib
nilotinib
nilotinib
drug evaluation
summary of product characteristics
package leaflet

---
http://www.meddispar.fr/Medicaments/TASIGNA-150-B-28/(type)/letter/(value)/T/(cip)/3400949815845
http://www.meddispar.fr/Medicaments/TASIGNA-150-B-112/(type)/letter/(value)/T/(cip)/3400949815906
2012
false
France
French
drug prescriptions
capsules
pyrimidines
legislation, drug
administration, oral
nilotinib
nilotinib
drug information

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-05/tasigna_-_ct-9624.pdf
http://www.has-sante.fr/portail/jcms/c_1050851/tasigna
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/tasigna_ct_9624.pdf
2011
false
France
French
English
evaluation of the transparency committee
Tyrosine Kinase Inhibitors
orphan drug production
leukemia, myeloid, chronic-phase
nilotinib
administration, oral
nilotinib
insurance, health, reimbursement
antineoplastic agents
protein-tyrosine kinases
pyrimidines

---
http://www.has-sante.fr/portail/jcms/c_1062535/tasigna-nilotinib-inhibiteur-de-tyrosine-kinase-synthese-d-avis
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-05/tasigna_-_ct-9624.pdf
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Tyrosine Kinase Inhibitors
administration, oral
nilotinib
pyrimidines
protein-tyrosine kinases
leukemia, myelogenous, chronic, bcr-abl positive
antineoplastic agents
orphan drug production
insurance, health, reimbursement
nilotinib
treatment outcome

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-5206_tasigna_.pdf
http://www.has-sante.fr/portail/jcms/c_642561/tasigna
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-04/tasigna_ct_5206.pdf
2008
false
France
French
English
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
nilotinib
protein-tyrosine kinases
orphan drug production
nilotinib
antineoplastic agents
pyrimidines
insurance, health, reimbursement
leukemia, myelogenous, chronic, bcr-abl positive
adult
administration, oral
treatment outcome
pyrimidines

---
Nous contacter.
11/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.